Fintent

An article by Mikheil Shengelia for Integrity Research Associates says the buy side has been a prominent user of alternative data since 2012 and that Eagle Alpha has worked with data-driven private equity firms since 2017.

The page lists a New York office at 240 Kent Avenue, Brooklyn, NY 11249, and the sales email sales@fintent.ai.

Fintent produces data and signals on private companies for VCs, PEs, IBs, and B2B lenders. It combines traditional and alternative data to predict SMB performance, trends, and corporate actions.

The page provides a contact form and a way to book a demo.

Fintent produces data and signals on private companies for VCs, PEs, and B2B lenders. It combines traditional and alternative data to predict SMB performance, trends, and corporate actions.

Fintent Inc's privacy notice explains how and why it may collect, store, use, and share information when people use its services, including visiting fintent.ai.

Fintent, an intelligence provider for investment banks and law firms, identifies key signals in consumer packaged goods (CPG), food, and retail sectors. The firm highlights emerging M&A trends and potential deal opportunities for October 2026. Research focuses on sector-specific shifts likely to influence dealmaking strategies.

Oct 2026The National Law ReviewNews article

Finent, an intelligence provider for investment banks and corporate law firms, releases its October 2026 research on M&A trends in consumer packaged goods (CPG), food, and retail. The report highlights key signals and opportunities for dealmakers in these sectors, focusing on strategic shifts and market dynamics. Insights aim to guide investment banks and legal advisors in identifying potential acquisition targets and partnerships.

Oct 2026The National Law ReviewNews article

Fintent analyzes M&A signals in Healthcare and Life Sciences to forecast potential deals for investment banks and corporate law firms. The company reviews proprietary data spanning May 18 to September 8, 2026, identifying trends and opportunities in sector transactions. Deal makers rely on its insights to anticipate strategic partnerships and acquisitions.

Sep 2026The National Law ReviewNews article

The healthcare and life sciences sector shows increased merger and acquisition (M&A) activity in five sub-sectors, including digital health, diagnostics, and biopharmaceuticals. Five other sub-sectors, such as medical devices and traditional pharmaceuticals, are experiencing a decline in deal volume. The report highlights shifting consolidation trends across the industry.

Sep 2026The National Law ReviewNews article